Company has changed due to financial pressures; discovery research drastically downsized. - Scientific Director Amgen Employee Review

3.0
Feb 16, 2015
Recommend
CEO approval
Business outlook

Pros

The company has lost its focus on internal discovery of new therapeutics; plan to in license or acquire more than 50% of future marketed therapies. Sadly, the halcyon days of George Rathman and Gordon Binder are long gone.

Cons

Too many layers of management slows down key decision making. Neuroscience Senior management lack appropriate scientific depth and expertise. Jealously guard their access to key opportunities. Senior Managers unwilling to relinquish control of scope and direction of new target discovery work to appropriate scientific leaders to the detriment of the company.

Explore other reviews about Amgen

5.0
Jun 26, 2026
Recommend
CEO approval
Business outlook

Pros

Flexible, good compensation, great team

Cons

may take meetings at odd hours due to global company

3.0
Jun 24, 2026
Recommend
CEO approval
Business outlook

Pros

Excellent compensation, benefits, and career development opportunities. Strong investment in innovation, patient-focused mission, and world-class manufacturing capabilities. The New Albany site offers exposure to complex biologics operations, large-scale capital projects, and opportunities to work alongside talented and dedicated professionals committed to delivering medicines to patients.

Cons

The culture and leadership experience became increasingly inconsistent during the last year. Decision-making often lacked transparency, priorities shifted frequently, and employee feedback did not always appear to be valued. The people-centered culture that attracted many long-tenured employees seemed to drift, resulting in reduced trust, lower engagement, and increased organizational uncertainty.

See reviews by: Helpful|Rating|Date|All